
I-Mab IMAB
Quartalsbericht 2025-Q4
hinzugefügt 11.04.2026
I-Mab Betriebszyklus 2011-2026 | IMAB
Betriebszyklus Jährlich I-Mab
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 271 | 15.5 | 4.65 | - | - | - | - | - | - | - | - |
Alle Zahlen in CNY-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 271 | 4.65 | 96.9 |
Betriebszyklus anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebszyklus | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
237 | $ 21.36 | 4.86 % | $ 998 M | ||
|
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
Akebia Therapeutics
AKBA
|
210 | $ 1.47 | 5.0 % | $ 378 M | ||
|
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | ||
|
Aquestive Therapeutics
AQST
|
223 | $ 4.19 | 2.7 % | $ 448 M | ||
|
Arcutis Biotherapeutics
ARQT
|
291 | $ 24.12 | -0.37 % | $ 3.07 B | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
321 | $ 32.59 | 1.09 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
129 | $ 1.47 | -1.34 % | $ 391 M | ||
|
Cidara Therapeutics
CDTX
|
2.26 K | - | - | $ 1.41 B | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | ||
|
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B | ||
|
Esperion Therapeutics
ESPR
|
99.7 | $ 2.22 | 2.3 % | $ 461 M | ||
|
Evogene Ltd.
EVGN
|
30 | $ 0.82 | 1.13 % | $ 27.9 M | ||
|
Baudax Bio
BXRX
|
126 | - | 0.59 % | $ 63 K | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B |